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L Process versus outcome: The sugar windowDavid A. Fullerton, MD,a and Thoralf M. Sundt, MDbAll cardiac surgical programs are focused on outcomes,
particularly rates of morbidity and mortality. It has
long been held that the ‘‘processes’’ of care lead to
‘‘outcomes.’’1 However, the relationship between processes
and outcomes is complex and indirect; outcomesmay be bad
even though the processes were optimal. But unlike true sur-
gical outcomes, elements of the processes of care may be
measured immediately and thereby provide an opportunity
for timely correction. Hence, there is logic to monitoring
process measures. A challenge arises, however, if questions
arise about the validity of the relationship between process
and outcome; one such performance measure is the control
of serum glucose in cardiac surgical patients.
In 1997, Zerr and colleagues2 retrospectively analyzed
data from diabetic cardiac surgical patients who underwent
operations between 1987 and 1993 and reported an
association of perioperative hyperglycemia and deep
wound infections. Reports from other cardiac surgical
investigators soon followed supporting this association
and suggesting that control of hyperglycemia through use
of a continuous insulin infusion (CII) might mitigate its
risk.3-6 For the most part, these reports were retrospective,
single-center studies demonstrating association but not
causality. The inference that tight glucose control would
benefit cardiac surgical patients was reinforced by van
den Berghe and colleagues,7 who in 2001 reported that an
insulin infusion protocol used to control hyperglycemia
reduced morbidity and mortality in a spectrum of critically
ill patients. Those groups looking on a national level for
levers to improve surgical outcomes noted these reports
and began to include postoperative glycemic control as a
measure of cardiac surgical quality.
The Medicare Surgical Infection Prevention (SIP) project
was begun in the fall of 2003, and hospitals began collecting
core measure data for SIP with patient discharges beginning
July 1, 2004. The SIP set of process measures subsequently
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2458 The Journal of Thoracic and Cardiovascular Sur(SCIP) measures effective July 1, 2006. The SCIP is a
partnership of national organizations with the laudable
commitment to reducing the rate of surgical complications.8,9
The SCIP partners include a steering committee with
representatives of 10 national organizations that support the
project. It has developed 20 process measures, of which
there are nine publicly reported SCIP measures; of these, six
focus on the prevention of postoperative infection. The
measures once established are monitored and updated
quarterly by a ‘‘technical expert panel’’ to ensure their validity.
One of the six infection-preventionSCIPmeasurespertains
to the control of postoperative serum glucose and has been in
effect since 2009. The Centers for Medicare and Medicaid
Services are the designated stewards of this measure respon-
sible for ongoing maintenance, and the measure has been
endorsed by theNationalQuality Forum.As originally imple-
mented, this SCIP measure called for the 6:00 AM serum
glucose on postoperative days 1 and 2 to be less than 200
mg/dL in cardiac surgical patients. Effective January 1,
2014, this measure was changed: the serum glucose is to be
less than 180 mg/dL during postoperative hours 18 to 24.
The time interval begins at the ‘‘anesthesia end time.’’10
There are strong financial incentives for hospitals to
comply with the SCIP measures. Collection of these data
by hospitals is voluntary. However, failure to report
performance on these measures results in a 2% reduction
hospital reimbursement from the Centers for Medicare and
Medicaid Services.11 The results of a given hospital’s data
are reported on the Hospital Compare Web site (http://
www.hospitalcompare.hhs.gov).11 Further, beginning in
2014, hospital reimbursement is penalized for failure to
achieve the measures under the ‘‘value-based purchasing’’
byCenters forMedicare andMedicaid Services, jeopardizing
millions of dollars per year of a given hospital’s revenue.
Therefore, hospitals place significant emphasis on SCIP
measure compliance. Unfortunately, pursuit of compliance
with such measures can be vexing at the least and arguably
counterproductive at the worst. Cardiac surgical programs
are being forced to build robust systems of care around
the imperative to control the serum glucose level despite
flimsy evidence to support their validity.
Hyperglycemia seems to be a ubiquitous finding in
postoperative cardiac surgical patients. Efforts to comply
with the SCIP measure have led to a maddening obsession
with even minor elevations in serum glucose during the
time in which the process measure is determined, the
‘‘sugar window.’’ The effort to avoid even minor elevations
of glucose can lead to perverse activities that may actually
be harmful, such as patients not being fed until aftergery c December 2014
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postoperative convalescent progress.
The administration of a CII is now commonplace as
prophylaxis against even the possibility of postoperative
hyperglycemia, adding cost and complexity to the care of
the patient. This is done despite evidence that even a CII
provides no assurance of achieving compliance with the
glucose measure.12,13 The safe practice of CII use, of
course, often requires that a patient be monitored in an
intensive care unit even in the absence of other reasons for
the patient to be there, artificially prolonging postoperative
intensive care unit stays and thereby increasing hospital
length of stay and costs. This is surely counter to
simultaneous pressures to improve the ‘‘value equation’’
of cost/quality in health care. In some cardiac surgical
programs, patients routinely receive a CII for the first 72
hours postoperatively to control serum glucose!14
The subject of compliance (and therefore noncompliance)
with the glucose measure is a constant topic of hospital
quality meetings, further absorbing efforts that might be
better spent elsewhere and increasing administrative costs.
A cottage industry of consultants has sprung up eager to offer
advice on how a given hospital may comply. One of us
(D.A.F.) receives weekly reports from the hospital ‘‘glucose
investigators’’ that describe in detail each instance of
noncompliance. Efforts to comply with the glucose SCIP
measure have emerged as a dominant focus in cardiac
surgical programs across the country. All of this is happening
despite the lack of evidence that compliance with the SCIP
processmeasure of glucose control actually improves quality.
The literature does not support the glucose SCIP measure
as a quality metric. To the contrary, a growing body of data
demonstrates no difference in morbidity or mortality in
patients that do or do not comply with the glucose SCIP
measure.11,12,15 Further, compliance with the glucose
control SCIP measure does not reflect glycemic control
during the perioperative period.12,13
More importantly, efforts to comply with this
performance metric may be harmful. The risk of iatrogenic
hypoglycemia induced by attempted SCIP measure
compliance is real and may jeopardize patient safety. The
Normoglycemia in Intensive Care Evaluation–Survival
Using Glucose Algorithm Regulation (NICE-SUGAR)
study confirmed an increased mortality from iatrogenic
hypoglycemia in the group of patients treated with
aggressive glycemic control.16 It is ironic that no require-
ment exists for the reporting of iatrogenic hypoglycemia.
We appreciate that it is difficult to determine quality in
surgical care and that although the outcome is the most
important variable to measure, an argument can be made
for measuring the process by which outcomes are derived.
But when the focus is so intensely placed on individual
process measures of care disconnected from the outcome,
particularly when a given process measure may be harmful,The Journal of Thoracic and Cara significant problem exists. It is a mistake to place such
emphasis on questionable process measures and to link
them to millions of dollars of hospital reimbursement.
Such focus implies that process measures are ‘‘quality’’ in
and of themselves, rather than simply tools by which
good outcomes may be attained.
There can be no question that the profession of
cardiothoracic surgery is one committed to quality. The
fact that greater than 95% of all cardiac surgical programs
voluntarily submit data on each patient to a national
database and approximately 50% of these programs
publically report their data voluntarily speaks to this
commitment. The question is: who is in the best position
to determine what constitutes quality in cardiac surgery?
The answer is the profession itself. It is the profession that
is most invested, knowledgeable, and capable. Especially
now, at the cusp of significant change in the financial model
of health care, it is incumbent upon the profession to
determine and continuously reevaluate the quality metrics
of cardiothoracic surgical care. We must step up and insist
on a voice in evaluating and maintaining appropriate
national measures to ensure that they are in alignment with
the laudable intent of their sponsors. We should insist
through our national organizations on a place at the table.References
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